Print

Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of over 15 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb

UCB FY Consensus Product Sales Estimates (Average)

In € million 2019a 2020e 2021e 2022e  2023e  2024e  2025e
Core Products              
Cimzia 1,712 1,845 1,936 1,992 1,972 1,841 1,642
Vimpat 1,322 1,453 1,563 1,399 851 652 526
Keppra  770 734 688 630 578 535 496
Briviact 221 295 367 435 498 554 598
Neupro 319 298 255 204 166 140 113
Potential new Product Launches
(global sales, non-risk adj.)
             
Evenity (romosozumab)   399  557  689  827 950  1,027
Midazolam nasal spray   19 40  58  78  92  102
Bimekizumab   65  228  434  634   834
Rozanolixizumab (Rozimab/Roza)   32  114 245  362
Padsevonil   18 49  92 116
Anti-Tau    0  0  0 100 228
Zilucoplan   0 0 86 192 328 497

 

UCB FY Consensus Earnings Estimates (Average)

In € million 2019a 2020e 2021e 2022e  2023e
Net Sales  4,680 4,983 5,287 5,377 5,137
Revenue  4,913 5,191 5,487 5,574 5,329
Recurring EBIT 1,118  1,078 1,270 1,405 1,320
Recurring EBITDA 1,431  1,424 1,621 1,754 1,674
Net Profit*  792 760 925 1,046 982
Core EPS (€) 5.20  4.92 5.78 6.40 6.11

*attributable to UCB shareholders  

UCB FY Consensus Product Sales Estimates (Median)

In € million 2019a 2020e 2021e 2022e  2023e  2024e  2025e
Core Products              
Cimzia 1,712 1,850 1,928 2,005 1,950 1,883 1,643
Vimpat 1,322 1,445 1,539 1,454 888 691 532
Keppra 770 726 672 622 571 524 484
Briviact 221 296 365 428 488 544 585
Neupro 319 307 254 204 175 147 107
Potential new Product Launches
(global sales, non-risk adj.)
             
Evenity (romosozumab)   411 576 682 829 912 974 
Midazolam nasal spray   19 40  63  82  101 112
Bimekizumab   67  210 390  600  850 
Rozanolixizumab (Rozimab/Roza)   20  100 237  327
Padsevonil   0 44 0
Anti-Tau    0 109  245 
Zilucoplan   0 0 76 173 283 403

 

UCB FY Consensus Earnings Estimates (Median)

In € million 2019a 2020e 2021e 2022e  2023e
Net Sales  4,680 4,983 5,261  5,329  5,153
Revenue  4,913 5,196 5,479 5,522 5,319
Recurring EBIT 1,118  1,101 1,284 1,424 1,395
Recurring EBITDA  1,431 1,417 1,620 1,732 1,713
Net Profit*  792  750 937 1,049 1,037
Core EPS (€) 5.20 4.91 5.85 6.42
6.36

*attributable to UCB shareholders

Downloads:
UCB FY 2019 Consensus (Excel)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated: 4 May, 2020



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.